Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Infographics

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

Why a focus on the provider is needed to achieve 4 or 5 Stars.

Principal, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Based on our analysis recently featured in the Wall Street Journal, the prevalence of no cost bronze coverage has increased significantly for 2018.

Principal, Oliver Wyman Actuarial Consulting
Practice Leader, Oliver Wyman Actuarial Consulting

Survey responses confirm that CSR defunding would have a significant impact on 2018 rates and payers’ continued participation in the ACA exchanges.

Partner, Oliver Wyman Actuarial Consulting
Practice Leader, Oliver Wyman Actuarial Consulting

A detailed look at what is driving 2018 premium rate increases.

Practice Leader, Oliver Wyman Actuarial Consulting

Insights in your inbox

Subscribe

With repeal and replace on pause, the reform spotlight is shifting to 1332 waivers, which give states the ability to waive some provisions of the ACA. A detailed look at the waiver process, state interest, and how health insurers might be impacted.

Partner, Oliver Wyman Actuarial Consulting
Senior Consultant, Oliver Wyman Actuarial Consulting

Oliver Wyman research reveals that majority of health insurers surveyed remain committed to the ACA exchanges, but with some tweaks and continued watchfulness.

Partner, Oliver Wyman Actuarial Consulting
Head of Health & Life Sciences, North America, Oliver Wyman